Huron Consul - HURN STOCK NEWS

Huron (NASDAQ: HURN) has successfully acquired Perception Health Inc., enhancing its healthcare predictive analytics and data capabilities. This strategic acquisition aims to help clients leverage data for improved patient care and decision-making. Huron's CEO, James H. Roth, expressed enthusiasm about integrating Perception Health's expertise to better identify and manage patient risks. Post-acquisition, Perception Health will be included in Huron's Healthcare operating segment, reinforcing their commitment to data-driven healthcare solutions.

Huron (NASDAQ: HURN) announced its agreement to acquire Perception Health Inc., a predictive analytics firm focused on healthcare. This acquisition aims to enhance Huron's capabilities in delivering data insights for improved clinical and business decisions. With Perception Health's advanced analytics and data platform, Huron seeks to support healthcare providers in lowering costs and improving patient outcomes. The acquisition is expected to close in December, although specific terms were not disclosed.

Huron has acquired Whiteboard Higher Education, enhancing its capabilities in student enrollment and financial aid strategies. This acquisition strengthens Huron's position to support colleges and universities in recruiting diverse student populations. The merger combines Whiteboard’s analytics and outreach expertise with Huron’s strategic enrollment solutions, aimed at meeting annual enrollment targets effectively. The deal, which closed today, will integrate Whiteboard into Huron's Education segment, aligning both companies towards improved student success outcomes.

Huron reported a 9.1% increase in revenues for Q3 2021, reaching $224.0 million compared to Q3 2020's $205.3 million. Net income rose 23.8% to $13.7 million, with diluted EPS from continuing operations up 28.0% to $0.64. Year-to-date revenues saw a 1.8% rise to $657.3 million. The company narrowed its 2021 revenue guidance to between $885.0 million and $905.0 million. Huron’s technology-related services contributed 40% to total revenue, indicating a strong focus on digital solutions.

Huron has finalized the divestiture of its life sciences commercial and R&D strategy business to Oliver Wyman, part of Marsh McLennan (NYSE: MMC). This strategic move allows Huron to focus more on enhancing its industry expertise in healthcare and education, alongside advancing its technology capabilities across all segments. The transaction is expected to streamline operations, directing resources towards core business areas, thereby aiming for improved client service and operational efficiency.

Huron (NASDAQ: HURN) is set to release its third-quarter financial results for the period ending September 30, 2021, after market hours on November 2, 2021. A conference call led by CEO James H. Roth and CFO John D. Kelly will occur the same day at 5:00 p.m. Eastern Time to discuss the results. The call will also be webcast on Huron's official website, with a replay available for 90 days post-event. Huron focuses on strategic growth and digital transformation for its clients.

Huron (NASDAQ: HURN) has signed an agreement to divest its Life Sciences Business to Oliver Wyman, a unit of Marsh McLennan (NYSE: MMC). This strategic move is aimed at enhancing Huron's focus on organic revenue growth and margin expansion. The Life Sciences Business contributed approximately 2% of Huron's total revenue for the nine months ended September 30, 2021. The transaction is anticipated to close in November 2021 and is projected to have minimal impact on Huron's full-year 2021 financial guidance. The company plans to use the proceeds to reduce debt and pursue strategic acquisitions.